
Opinion|Videos|April 26, 2024
TIVO-3: Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its impressions on the results.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
3
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
4
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
5






























